drugset / Trial / NCT00391846

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

NCT00391846

Phase 4 Completed 252 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction

Timeline

Start
2006-10
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Background Bisoprolol Other / unclassified
Background Candesartan Unknown
Background Captopril Small molecule
Background Carvedilol Other / unclassified
Background Enalapril Other / unclassified
Background Eplerenone Unknown
Background LISINOPRIL ANHYDROUS Small molecule
Background Metoprolol Other / unclassified
Background Ramipril Small molecule
Background Spironolactone Small molecule
Background Valsartan Small molecule
Background trandolapril Small molecule